Previous 10 | Next 10 |
WESTLAKE VILLAGE, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 18,900 restricted stock u...
Arcutis Biotherapeutics press release (NASDAQ:ARQT): Q4 GAAP EPS of -$1.42 beats by $0.18. Strong financial position with more than $385M in cash, cash equivalents, and marketable securities. For further details see: Arcutis Biotherapeutics GAAP EPS of -$1.42 beats by $0.18
Received U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis in adults and adolescents Completed enrollment of the sole pivotal Phase 3 trial of roflumilast foam in seborrheic dermatitis E...
Topline data now anticipated in mid-year 2022, followed by a regulatory submission in first half of 2023 A total of 457 subjects are enrolled in the STRATUM study Seborrheic dermatitis affects 10 million people in the U.S. WESTLAKE VILLAGE, Calif., Feb. 01, 2022 (GLOBE N...
Arcutis Biotherapeutics (NASDAQ:ARQT) has obtained a $225M term loan facility from funds managed by SLR Capital Partners. This additional capital further strengthens Arcutis’ balance sheet in advance of a potential 2022 FDA approval and launch of topical roflumilast cream in plaque pso...
WESTLAKE VILLAGE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it has obtained a $225 million term loan facility...
Arcutis Biotherapeutics (NASDAQ:ARQT) announces the FDA's acceptance for review of its new drug application (NDA) for roflumilast cream for psoriasis in adults and adolescents. The FDA assigned a PDUFA target action date of July 29, 2022. Arcutis’ NDA submission is supported by po...
FDA has set a target action date of July 29, 2022 NDA supported by positive efficacy data from the pivotal Phase 3 DERMIS 1 and DERMIS 2 clinical studies, as well as results from the long-term safety study If approved, roflumilast cream would be the first and only topical PDE4 inh...
Data presented at Revolutionizing Atopic Dermatitis (RAD) Conference Vehicle tested was comparable to the moisturizing cream based on primary endpoint of change in transepidermal water loss (TEWL) from baseline at Day 15 Data provide additional support for ongoing studies of inves...
WESTLAKE VILLAGE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology to address the urgent needs of patients living with immune-mediated der...
News, Short Squeeze, Breakout and More Instantly...
Arcutis Biotherapeutics Inc. Company Name:
ARQT Stock Symbol:
NASDAQ Market:
Arcutis Biotherapeutics Inc. Website:
ZORYVE cream provides rapid relief, with efficacy, safety, and tolerability demonstrated up to 56 weeks of treatment ZORYVE cream rapidly and significantly reduces itch, the most bothersome symptom of atopic dermatitis (AD) Once-daily cream is for use anywhere on the body for any duration...
WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that the Company has been in communication with the U....
2024-06-16 18:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...